Pairing a GHRH analogue with a GHS-R1a agonist is a long-standing design in secretagogue research, following the work of Bowers and colleagues showing that the two classes produce a greater combined response than either alone
The data isn't bulletproof (preparation methods vary, study quality is uneven), but it's further along than BPC-157's primarily animal evidence base
Oral administration allows for easy daily use without the discomfort, complexity or potential side effects associated with injections
If you dont reach your daily max, up to 4 points will roll over into your weekly point bank
To be direct about what this is and what it is not: IGF-1 LR3 is not a shortcut
Gradual Uptitration: Patients are closely monitored as the dose is gradually increased in increments of 0.1mg every few weeks, based on individual response and tolerability